EU Drug Safety Actions Speeded Up By New Legislation, Says Commission
Executive Summary
The European Commission reports that new regulatory tools made available under the revised pharmacovigilance legislation have allowed drug safety issues to be detected and acted upon more rapidly, and that further improvements to the system are in the pipeline.
You may also be interested in...
EFPIA Picks Holes With EMA's Revised Guidance On Risk Management Plans
The European Federation of Pharmaceutical Industries and Associations has welcomed most of the changes that the European Medicines Agency has proposed making to its guideline on risk management plans (RMPs), saying that the revisions would help remove "several redundancies present in the current version" of the guidance. However, EFPIA has significant concerns over certain other parts of the revised guideline, such as the rewording of certain sections that it believes could be misinterpreted by those enforcing the guideline and create confusion.
Don't Let Sponsors Downplay Genuine Safety Concerns At Public Hearings, HAI Tells EMA
After the European Medicines Agency's pharmacovigilance committee (PRAC) finalized rules on how it would conduct public hearings to support the safety review of certain marketed medicines earlier this month1-3, medicines advocacy group Health Action International said that it welcomed the move, but warned that drug sponsors should not be allowed to downplay genuine safety concerns at such hearings.
How Effective Is Pharmacovigilance? EMA Committee Intends To Find Out
'Impact studies' will allow regulators to determine which activities are successful and which are not.